CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case–control study

Verla-Tebit, Emaculate; Wang-Gohrke, Shan; Chang‐Claude, Jenny

doi:10.1186/bcr1027

Cited by 18 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with our results, Verla-Tebit et al (2005) found no evidence of the previously reported (Feigelson et al 1997;Ambrosone et al 2003) effect modification for later age at menarche by the CYP 17 TT (A1/A1) genotype. Verla-Tebit et al (2005) observed an increased risk for oral contraceptive users compared with nonusers among nulliparous women with the TT (A1/A1) genotype.…”

Section: Discussionsupporting

confidence: 90%

“…Similar findings were reported by Verla-Tebit et al (2005). It was reported that early pregnancy has a protective role against breast cancer; women whose FFTP occur after the age of 30 have a two to fivefold increase in breast cancer risk compared with women having a FFTP before age of 20.…”

Section: Discussionsupporting

confidence: 86%

“…They argued that oral contraceptive use might affect risk only in an environment of lower estrogens seen in carriers of the TT (A1/ A1) genotype. There is consistency between the German (Verla-Tebit et al 2005) and Australian studies of premenopausal women in the lack of evidence of a differential effect of CYP17 genotype on risk associated with age at menarche, age at first birth, or use of oral contraceptives. In contrast to the German study (Verla-Tebit et al 2005), neither the Swedish (Einarsdottir et al 2005) nor Australian ) studies showed an increased risk associated with presence of the C (A2) allele in nulliparous premenopausal women.…”

Section: Discussionmentioning

confidence: 88%

“…Verla-Tebit et al (2005) observed an increased risk for oral contraceptive users compared with nonusers among nulliparous women with the TT (A1/A1) genotype. Ambrosone et al (2003) reported similar findings, though this was for all premenopausal women and not only in the nulliparous group.…”

Section: Discussionmentioning

confidence: 93%

“…Extraction of genomic DNA from peripheral blood leucocytes was performed using DNA extraction kit QIAamp (DNA Blood Mini Kit) supplied by QIAGEN, Hilden, Germany. CYP 17-34T>C (rs743572) genotypes were investigated by means of PCR-RFLP as previously described (Verla-Tebit et al 2005). Each PCR reaction was carried out with 50 ng of genomic DNA, 20 pmole of each primer, and 12.5 μl of master mix (Dream Taq TM , Green PCR Master Mix , Fermentas Life Sciences, Vilnius, Lithuania) in a total volume of 25 μl.…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

CYP 17 and estrogen receptor α gene polymorphisms: association with breast cancer susceptibility and clinicopathological parameters in a cohort of Egyptian patients

et al. 2013

View full text Add to dashboard Cite

The association between exposure to endogenous and exogenous steroid hormones and breast cancer (BC) risk is well established. The aim of this study was to examine whether Cytochrome P450 (CYP)17 -34T>C and estrogen receptor (ER)α XbaI gene polymorphisms might influence endogenous estrogen hormone level. Also, we aimed to examine the potential association between these polymorphisms and BC risk, as well as some clinicopathological parameters in BC patients. Eightyone Egyptian female subjects were recruited; 41 pathologically confirmed BC patients and 40 apparently healthy, age-matched female control subjects. Serum estradiol level was assayed using radioimmunoassay. Polymerase chain reaction-restriction fragment length polymorphism technique was used for detection of CYP 17 -34T>C and ERα -XbaI polymorphisms. Serum estradiol level did not show statistically significant difference when compared between the different CYP17 and ERα genotypes in controls (p =0.088 and 0.241, respectively). No significant association between CYP17 and ER α gene polymorphisms and BC risk was encountered. There was a statistically significant association between ER α genotypes in overall BC cases with each of age at menarche, p =0.024, age at diagnosis, p =0.011, and nodal involvement, p =0.037, and between nodal number and ER α genotypes in the premenopausal BC group, p =0.038. In conclusion, CYP17 and ERα genotypes did not influence serum estradiol level. No statistically significant association was found between CYP17 -34T>C and ERα XbaI gene polymorphisms and breast cancer risk in Egyptian women. ER α gene may have an association with some clinicopathological parameters in breast cancer in Egyptian patients.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 93%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

CYP 17 and estrogen receptor α gene polymorphisms: association with breast cancer susceptibility and clinicopathological parameters in a cohort of Egyptian patients

et al. 2013

View full text Add to dashboard Cite

show abstract

Genetic Polymorphisms Predisposing Individuals to Breast Cancer Via Gene–Environment Interaction

Yoo

Park

Shin

2010

Environmental Factors, Genes, and the Development of Human Cancers

View full text Add to dashboard Cite

No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects

Yao

Fang

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

Breast cancer is one of the most common malignant tumors worldwide. To date, many articles have evaluated the association between Cytochrome P450c17 (CYP17) T-34C polymorphism and breast cancer risk. However, the results remain inconclusive. In order to derive a more precise estimation of the association, a meta-analysis was performed in this study. By searching Medline, ISI Web of Knowledge, Cochrane, ScienceDirect, EBSCO, CNKI, and SinoMed databases, 43 studies including 26,008 cases and 32,806 controls were collected for CYP17 T-34C polymorphism. Crude ORs with 95% CIs were used to assess the strength of association between CYP17 T-34C polymorphism and breast cancer risk. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively. Overall, no significant associations between CYP17 T-34C polymorphism and breast cancer susceptibility were found for TT versus CC (OR = 0.96; 95% CI: 0.89-1.05), TC versus CC (OR = 0.97; 95% CI: 0.89-1.06), TT + TC versus CC (OR = 0.97; 95% CI: 0.89-1.05) and TT versus TC + CC (OR = 0.98; 95% CI: 0.93-1.03). In the stratified analysis by ethnicity, menopausal status, and sources of controls, significant associations were still not detected in all genetic models. In conclusion, this meta-analysis strongly suggests that CYP17 T-34C polymorphism is not associated with breast cancer risk.

show abstract

CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case–control study

Cited by 18 publications

References 27 publications

CYP 17 and estrogen receptor α gene polymorphisms: association with breast cancer susceptibility and clinicopathological parameters in a cohort of Egyptian patients

CYP 17 and estrogen receptor α gene polymorphisms: association with breast cancer susceptibility and clinicopathological parameters in a cohort of Egyptian patients

Genetic Polymorphisms Predisposing Individuals to Breast Cancer Via Gene–Environment Interaction

No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects

Contact Info

Product

Resources

About